PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. (2022). PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS. EKB Journal Management System, 4(3), 30-31. doi: 10.21608/alexpo.2022.160356.1463
Ashraf Hussein El Ghandour; abeer shawky elhadidi; Omar Mohamed Ghallab; Eman Attia Nadwan; Reem Abdelwahab Eshra. "PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS". EKB Journal Management System, 4, 3, 2022, 30-31. doi: 10.21608/alexpo.2022.160356.1463
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. (2022). 'PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS', EKB Journal Management System, 4(3), pp. 30-31. doi: 10.21608/alexpo.2022.160356.1463
El Ghandour, A., elhadidi, A., Ghallab, O., Nadwan, E., Eshra, R. PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS. EKB Journal Management System, 2022; 4(3): 30-31. doi: 10.21608/alexpo.2022.160356.1463

PROTEIN ARGININE METHYLTRANSFERASE 1 EXPRESSION LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS

ALEXMED ePosters
Article 3, Volume 4, Issue 3, September 2022, Page 30-31  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.160356.1463
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Hussein El Ghandour1; abeer shawky elhadidi2; Omar Mohamed Ghallab3; Eman Attia Nadwan1; Reem Abdelwahab Eshra email 4
1Department of Internal Medicine (Hematology Unit), Faculty of Medicine , Alexandria University
2department of chemical and clinical pathology, Faculty of medicine.
3department of internal medicine hematology unit
4Haematology Unit, Internal Medicine Department, Alexandria University, Egypt
Abstract
AML is a haematological malignancy characterized by a wide range of mutated genes and a wide genomic architecture composed of preleukemic and leukemic clones that unfold progressively over time. Protein arginine methylation is a posttranslational modification that is activated by the PRMT family of which PRMT1 is the most predominant isoform. PRMT1 was reported to be upregulated in breast cancer, lung cancer and colon cancer and to promote the proliferation and transformation of cancer cells. While the detailed function of PRMT1 in adult hematopoietic stem and progenitor cells (HSPCs) self-renewal and differentiation is still largely unknown, the role of PRMT1 in normal adult hematopoiesis has recently been identified.
Aim:
To evaluate the impact of the PRMT1 on response to induction chemotherapy in adult Egyptian AML patients.
Patients & Methods:
The presented study was conducted on 40 newly diagnosed AML patients in Alexandria University Main Hospital, Internal Medicine Department, Haematology Unit, from the period of December 2020 to August 2021. All of our patients were tested for PRMT1 gene expression level in bone marrow aspirate samples at time of initial diagnosis, as well as 20 healthy control subjects. Patients received standard [7+3] AML induction chemotherapy and follow up BMA assessment was done at day 28, assessing response to induction.
Keywords
PRMT1; ACUTE MYELOID LEUKEMIA; hematology
Supplementary Files
Statistics
Article View: 126